Your session is about to expire
← Back to Search
Cancer Vaccine
Pembrolizumab + Vaccine for Glioblastoma
Phase 1
Recruiting
Led By Timothy F Cloughesy
Research Sponsored by Jonsson Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Creatinine =< 1.5 x upper limit of normal (ULN) OR measured or calculated creatinine clearance >= 30 mL/min for participant with creatinine levels > 1.5 x institutional ULN (collected within 14 days prior to the start of study treatment) (glomerular filtration rate [GFR] can also be used in place of creatinine or creatinine clearance [CrCl])
Criteria must be met without erythropoietin dependency and without packed red blood cell (pRBC) transfusion within last 2 weeks
Must not have
Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug
Has known tumor primarily localized to the brainstem or spinal cord
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 6 years
Summary
This trial is testing a combination of an immunotherapy drug, pembrolizumab, and a vaccine, ATL-DC, in patients with recurrent glioblastoma that can be surgically removed. The goal is to see if this combination can help the immune system better attack the cancer and improve patient outcomes.
Who is the study for?
This trial is for adults with recurrent glioblastoma that can be surgically removed. They must have a tumor of a certain size, not be on immunosuppressive therapy, and agree to use contraception. Excluded are pregnant or breastfeeding women, those with recent other cancer treatments or live vaccines, severe allergies to pembrolizumab, active infections like HIV or hepatitis B/C, and autoimmune diseases treated within the last 2 years.
What is being tested?
The trial tests how well pembrolizumab (an antibody) works alongside an ATL-DC vaccine in treating recurrent glioblastoma compared to the vaccine alone. The study aims to see if this combination helps the immune system better attack cancer cells and prevent their growth.
What are the potential side effects?
Possible side effects include reactions at the injection site from the vaccine and typical immune-related adverse effects from pembrolizumab such as fatigue, skin issues, inflammation of organs like lungs or intestines (pneumonitis/colitis), hormonal imbalances due to thyroid gland problems.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My kidney function, measured by creatinine or GFR, is within the required range.
Select...
I haven't had a blood transfusion or taken erythropoietin in the last 2 weeks.
Select...
It has been at least 28 days since my last surgery.
Select...
I can provide a tissue sample from my brain tumor for testing.
Select...
I am able to care for myself but may not be able to do active work.
Select...
My glioblastoma has returned or worsened and can be operated on.
Select...
My tumor is at least 2cm by 2cm in size, confirmed by MRI.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have an immune system disorder or have been on high-dose steroids or other immune-weakening medicines recently.
Select...
My tumor is mainly in my brainstem or spinal cord.
Select...
I have an active tuberculosis infection.
Select...
I have not received a live vaccine in the last 30 days.
Select...
I haven't needed systemic treatment for an autoimmune disease in the last 2 years.
Select...
I have another cancer that is getting worse or was treated in the last 3 years.
Select...
I have a history of hepatitis B or active hepatitis C.
Select...
I have had or currently have lung inflammation treated with steroids.
Select...
I have been treated with specific immune therapy targeting cancer.
Select...
I am currently being treated for an infection.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 6 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 6 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Expansion of T cell receptor (TCR) clones
Incidence of adverse events (AEs)
Secondary study objectives
6 month progression-free survival (PFS6)
Overall survival (OS)
Other study objectives
Biomarker analysis
T cell subset and activation markers within peripheral blood measured by flow cytometry
TIL (tumor infiltrating lymphocyte) density and TCR (T cell receptor) Clonality in the tumor quantitatively measured by next generation TCR sequencing
+4 moreSide effects data
From 2024 Phase 3 trial • 804 Patients • NCT0304099964%
Radiation skin injury
63%
Stomatitis
58%
Anaemia
56%
Nausea
48%
Dry mouth
45%
Constipation
45%
Weight decreased
44%
Dysphagia
42%
Neutrophil count decreased
33%
Dysgeusia
33%
Vomiting
32%
Fatigue
31%
White blood cell count decreased
28%
Hypomagnesaemia
26%
Decreased appetite
25%
Hypothyroidism
25%
Hypokalaemia
24%
Lymphocyte count decreased
24%
Platelet count decreased
23%
Oropharyngeal pain
23%
Blood creatinine increased
22%
Diarrhoea
22%
Odynophagia
20%
Hypoacusis
20%
Alanine aminotransferase increased
20%
Hyponatraemia
19%
Tinnitus
19%
Oral candidiasis
19%
Asthenia
16%
Pyrexia
16%
Cough
15%
Aspartate aminotransferase increased
15%
Rash
14%
Insomnia
13%
Acute kidney injury
13%
Pharyngeal inflammation
13%
Pruritus
12%
Dysphonia
12%
Gamma-glutamyltransferase increased
11%
Pneumonia
11%
Dehydration
10%
Hyperthyroidism
10%
Hypoalbuminaemia
10%
Hypocalcaemia
10%
Headache
10%
Productive cough
9%
Neck pain
9%
Peripheral sensory neuropathy
8%
Gastrooesophageal reflux disease
8%
Hiccups
8%
Hyperglycaemia
8%
Hyperuricaemia
8%
Dizziness
8%
Hypophosphataemia
7%
Urinary tract infection
7%
Ear pain
7%
Localised oedema
7%
Hyperkalaemia
7%
Erythema
7%
Oral pain
6%
Abdominal pain upper
6%
Arthralgia
6%
Anxiety
6%
Febrile neutropenia
6%
Dyspepsia
6%
Saliva altered
5%
Back pain
5%
Oedema peripheral
5%
Hypertension
5%
Dyspnoea
4%
Nasopharyngitis
4%
Alopecia
4%
Dry skin
3%
Sepsis
3%
Pneumonia aspiration
3%
Trismus
3%
Pneumonitis
3%
Laryngeal oedema
2%
Malnutrition
2%
Pharyngeal haemorrhage
2%
Cellulitis
1%
Septic shock
1%
Systemic infection
1%
Clostridium difficile colitis
1%
Cardiac arrest
1%
Death
1%
Bronchitis
1%
Hepatitis
1%
Immune-mediated hepatitis
1%
Oesophagitis
1%
General physical health deterioration
1%
Hypophagia
1%
Tumour haemorrhage
1%
Cerebrovascular accident
1%
Syncope
1%
Acute respiratory failure
1%
Aspiration
1%
Colitis
1%
Mouth haemorrhage
1%
Hypersensitivity
1%
Acute myocardial infarction
1%
Abscess neck
1%
Device related infection
1%
Stoma site infection
1%
Vascular device infection
1%
Wound infection
1%
Hypercalcaemia
1%
Pulmonary embolism
1%
Respiratory failure
100%
80%
60%
40%
20%
0%
Study treatment Arm
Pembrolizumab + CRT Followed by Pembrolizumab
Placebo + CRT Followed by Placebo
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Group A (pembrolizumab, ATL-DC, poly ICLC)Experimental Treatment3 Interventions
Beginning 14 days prior to scheduled surgery, patients receive pembrolizumab IV over 30 minutes. After surgery, patients receive pembrolizumab IV over 30 minutes on day 1. Cycle repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive ATL-DC ID with poly ICLC IM every 2 weeks for up to 3 doses in the absence of disease progression or unacceptable toxicity.
Group II: Group B (placebo, ATL-DC, poly ICLC)Active Control3 Interventions
Beginning 14 days prior to scheduled surgery, patients receive placebo IV. After surgery, patients receive placebo IV on day 1. Cycle repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive ATL-DC ID with poly ICLC IM every 2 weeks for up to 3 doses in the absence of disease progression or unacceptable toxicity.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pembrolizumab
2017
Completed Phase 3
~3130
Poly ICLC
2014
Completed Phase 2
~270
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Pembrolizumab, a PD-1 inhibitor, blocks the PD-1 pathway that tumors use to evade the immune system, thereby enhancing the immune system's ability to recognize and attack cancer cells. The ATL-DC vaccine stimulates the immune system by presenting tumor antigens to immune cells, boosting the body's ability to target and destroy glioblastoma cells.
These treatments are significant for Glioblastoma patients as they leverage the body's immune system for a more targeted and potentially effective approach to combating the cancer.
Find a Location
Who is running the clinical trial?
Merck Sharp & Dohme LLCIndustry Sponsor
4,032 Previous Clinical Trials
5,189,760 Total Patients Enrolled
31 Trials studying Glioblastoma
3,720 Patients Enrolled for Glioblastoma
Phase One FoundationOTHER
4 Previous Clinical Trials
263 Total Patients Enrolled
1 Trials studying Glioblastoma
19 Patients Enrolled for Glioblastoma
National Cancer Institute (NCI)NIH
13,957 Previous Clinical Trials
41,112,077 Total Patients Enrolled
330 Trials studying Glioblastoma
23,347 Patients Enrolled for Glioblastoma
Oncovir, Inc.Industry Sponsor
23 Previous Clinical Trials
603 Total Patients Enrolled
1 Trials studying Glioblastoma
19 Patients Enrolled for Glioblastoma
Jonsson Comprehensive Cancer CenterLead Sponsor
370 Previous Clinical Trials
35,087 Total Patients Enrolled
18 Trials studying Glioblastoma
510 Patients Enrolled for Glioblastoma
Timothy F CloughesyPrincipal InvestigatorUCLA / Jonsson Comprehensive Cancer Center
1 Previous Clinical Trials
29 Total Patients Enrolled
1 Trials studying Glioblastoma
29 Patients Enrolled for Glioblastoma
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- My liver function tests are within the required range.I have recovered from any major surgery before starting the study treatment.I am eligible for a surgery to remove at least 2 grams of my tumor safely.I have an immune system disorder or have been on high-dose steroids or other immune-weakening medicines recently.You have a severe allergic reaction (grade 3 or higher) to pembrolizumab or any of its ingredients.My tumor is mainly in my brainstem or spinal cord.I have an active tuberculosis infection.It's been over 12 weeks since my last radiotherapy, or I have confirmed tumor growth since then.I have not received a live vaccine in the last 30 days.I had radiotherapy over 2 weeks ago, with no ongoing side effects and didn't need steroids.My cancer has returned once or twice after treatment.I agree to use contraception and not donate sperm for 120 days after my last treatment dose.My kidney function, measured by creatinine or GFR, is within the required range.My blood clotting time is normal or managed if I'm on blood thinners.My blood clotting time is normal or near normal, even if I'm on blood thinners.I haven't needed systemic treatment for an autoimmune disease in the last 2 years.I am not pregnant, can test for it, and will use birth control during and after the study.I have another cancer that is getting worse or was treated in the last 3 years.I haven't had a blood transfusion or taken erythropoietin in the last 2 weeks.It has been at least 28 days since my last surgery.I have a history of hepatitis B or active hepatitis C.It has been over a week since my last stereotactic biopsy.I can provide a tissue sample from my brain tumor for testing.I have had or currently have lung inflammation treated with steroids.I am able to care for myself but may not be able to do active work.My glioblastoma has returned or worsened and can be operated on.I have been treated with specific immune therapy targeting cancer.It has been over 23 days since my last chemotherapy session.My recent MRI shows my tumor is growing.I have had cancer treatment, including trial drugs, within the last 4 weeks.I am currently being treated for an infection.My tumor is at least 2cm by 2cm in size, confirmed by MRI.I have recovered from side effects of previous treatments, except for mild neuropathy.I had skin cancer or early-stage breast or cervical cancer but was treated for a cure.It has been over 42 days since my last nitrosureas treatment.
Research Study Groups:
This trial has the following groups:- Group 1: Group A (pembrolizumab, ATL-DC, poly ICLC)
- Group 2: Group B (placebo, ATL-DC, poly ICLC)
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.